News
4 M$ investment agreement to prepare the clinical study of an improved chemotherapy
October 30th, 2024
Opening of the 2nd tranche of OpPacli™'s preclinical round
October 30th, 2024
First patents granted to Pharma in silica
January 29th, 2024
Pharma in silica receives positive feedback from FDA and Health Canada, paving the way for OpPacli™ clinical trials
November 20th, 2023
$ 2M toward an efficient and lenient chemotherapy: the government of Québec and 6 individual investors enter the capital of Pharma in silica
May 2nd, 2023
Ms. Isabelle Tremblay joins the board of directors of Pharma in silica
December 28th, 2022
Pharma in silica acquires the founding intellectual property on the OpKemo technology
July 29th, 20232
Pharma in silica launches its first preclinical program
June 1st 2022
Pharma in silica's scientific coordinator takes up her post
April 15th, 2022
Conclusion of the OptiSpheres 3 program
July 15th, 2021
Pharma in silica inaugurates its new high-safety laboratory
November 4th, 2020
The City of Québec financially supports Pharma in silica
February 3rd, 2020
Mr Bertrand Bolduc joins Pharma in silica inc.'s board of directors
November 18th, 2019
For a safe chemotherapy: Pharma in silica starts up
August 30th, 2019
Conclusion of the OptiSpheres 3 program
Quebec City, July 15, 2021 - Pharma in silica announces the conclusion of the research program OptiSpheres 3.
The development of two original biodistribution assays in mouse models and the development of the second-generation prototype of OpPacli™ (optimized paclitaxel) prototype are among the main results of the program.
The work was carried out in collaboration with SiliCycle chemists and the teams of Professors Nicolas Bertrand and Marc-André Fortin of the CHU de Québec/Université Laval.
About Pharma in silica inc.
Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.
For more information
François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com
> all news